Galectin Therapeutics (NASDAQ:GALT) Raised to Hold at StockNews.com

Galectin Therapeutics (NASDAQ:GALTGet Free Report) was upgraded by stock analysts at StockNews.com from a “sell” rating to a “hold” rating in a report released on Tuesday.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $11.00 price objective on shares of Galectin Therapeutics in a research report on Tuesday, April 9th.

Get Our Latest Report on Galectin Therapeutics

Galectin Therapeutics Stock Down 3.7 %

GALT opened at $3.11 on Tuesday. The stock has a market cap of $193.29 million, a PE ratio of -4.20 and a beta of 0.72. The business has a 50 day moving average of $3.08 and a 200-day moving average of $2.27. Galectin Therapeutics has a 52 week low of $1.28 and a 52 week high of $4.27.

Galectin Therapeutics (NASDAQ:GALTGet Free Report) last released its earnings results on Wednesday, May 15th. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.03). Equities analysts anticipate that Galectin Therapeutics will post -0.66 EPS for the current year.

Insider Activity at Galectin Therapeutics

In related news, major shareholder James C. Czirr sold 21,323 shares of the firm’s stock in a transaction that occurred on Monday, April 22nd. The stock was sold at an average price of $3.06, for a total transaction of $65,248.38. Following the completion of the transaction, the insider now owns 5,925,884 shares of the company’s stock, valued at approximately $18,133,205.04. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders purchased a total of 4,500 shares of company stock valued at $14,360 in the last 90 days. Corporate insiders own 52.70% of the company’s stock.

Institutional Trading of Galectin Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. increased its holdings in shares of Galectin Therapeutics by 2.0% in the 1st quarter. Vanguard Group Inc. now owns 1,979,891 shares of the company’s stock worth $4,732,000 after purchasing an additional 38,037 shares in the last quarter. Wealthspire Advisors LLC grew its holdings in shares of Galectin Therapeutics by 116.7% in the first quarter. Wealthspire Advisors LLC now owns 398,374 shares of the company’s stock worth $952,000 after acquiring an additional 214,512 shares during the period. Retirement Guys Formula LLC grew its holdings in shares of Galectin Therapeutics by 56.9% in the first quarter. Retirement Guys Formula LLC now owns 33,732 shares of the company’s stock worth $81,000 after acquiring an additional 12,232 shares during the period. Solutions 4 Wealth Ltd bought a new stake in shares of Galectin Therapeutics in the fourth quarter worth $60,000. Finally, Beacon Capital Management LLC grew its holdings in shares of Galectin Therapeutics by 89.6% in the fourth quarter. Beacon Capital Management LLC now owns 23,905 shares of the company’s stock worth $40,000 after acquiring an additional 11,300 shares during the period. Institutional investors own 11.68% of the company’s stock.

About Galectin Therapeutics

(Get Free Report)

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.

See Also

Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.